Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma.

Trial Profile

Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Bortezomib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 06 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 13 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top